James Turek, MD
General Practice · Murrells Inlet, SCNPI 1942360672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Among general practice clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$994
- Novo Nordisk$547
- AstraZeneca$463
- GSK$449
- Pfizer$338
- Amarin Pharma, Inc.$227
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$1503%
- Food & beverage$4,63596%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $994 |
| Novo Nordisk | 32 | $547 |
| AstraZeneca | 29 | $463 |
| GSK | 25 | $449 |
| Pfizer | 21 | $338 |
| Amarin Pharma, Inc. | 15 | $227 |
| Daiichi Sankyo Inc. | 11 | $214 |
| Amgen | 13 | $209 |
| Exact Sciences | 12 | $201 |
| Galderma Laboratories, L.p. | 1 | $150 |
| Dexcom, Inc. | 4 | $135 |
| Sanofi-aventis U.S. LLC | 5 | $131 |
| Abbott | 5 | $100 |
| Lilly USA, LLC | 6 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $56 |
| Boehringer Ingelheim | 2 | $54 |
| Phathom Pharmaceuticals, Inc. | 6 | $54 |
| Merck | 4 | $46 |
| Corcept Therapeutics | 2 | $37 |
| Mylan Specialty L.p. | 2 | $35 |
| Averitas Pharma Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Alkermes, Inc. | 1 | $25 |
| Nevro Corp. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Merz North America, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Medtronic | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
| Boston Scientific | 1 | $12 |
How this compares
$4,835 in reported general payments places this provider in the 95th percentile of 1,367 general practice providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $103,010 |
| FarxigaDapagliflozin Propanediol | 74 | $88,684 |
| OzempicSemaglutide | 70 | $78,209 |
| JardianceEmpagliflozin | 41 | $57,352 |
| JanuviaSitagliptin Phosphate | 41 | $56,803 |
| CreonLipase/Protease/Amylase | 11 | $49,546 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $47,491 |
| VraylarCariprazine Hcl | 24 | $36,452 |
| XareltoRivaroxaban | 27 | $34,195 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $30,928 |
| TrulicityDulaglutide | 16 | $20,378 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,133 |
| Rosuvastatin Calcium | 375 | $7,641 |
| Atorvastatin Calcium | 659 | $6,923 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 154 | $5,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $338 | $103,01083 claims |
| AbbVieCreon, Vraylar, Synthroid | $994 | $89,67191 claims |
| AstraZenecaFarxiga | $463 | $88,68474 claims |
| MerckJanuvia, Janumet | $46 | $87,73067 claims |
| Novo NordiskOzempic | $547 | $78,20970 claims |
| Boehringer IngelheimJardiance | $54 | $57,35241 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $449 | $56,62469 claims |
| Johnson & JohnsonXarelto | $15 | $34,19527 claims |
| Lilly USA, LLCTrulicity | $85 | $20,37816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,367 general practice providers in South Carolina.
Other general practice in Murrells Inlet
- Jeffrey HorowitzMurrells Inlet$152K
- Joseph GrantSumter$187K
- Christopher CampbellLexington$166K
- Amanda SeayMount Pleasant$146K
- Jon JulianTravelers Rest$141K
- Timothy SniderGreenwood$122K
- Anthony MennitoBamberg$120K
- Coty FishburneRock Hill$119K
- Rukudzo MazaiwanaOrangeburg$70K
- Benjamin DanielGreenville$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.